Trial Profile
Phase II study of S-1 for relapsed or refractory thymoma or thymic carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Feb 2021
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Malignant thymoma; Thymoma
- Focus Therapeutic Use
- 20 Dec 2019 Status changed from recruiting to completed.
- 20 Jun 2012 New trial record